Rain Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Rain Therapeutics Inc. (NasdaqGS: RAIN) announced that its CEO, Avanish Vellanki, will partake in two upcoming virtual conferences: the Piper Sandler 33rd Annual Healthcare Conference from November 29 to December 2, 2021, and the Evercore ISI 4th Annual Health CONx Virtual Conference on December 2, 2021. The Piper Sandler presentation will be available starting November 22, 2021, at 10:00 a.m. ET. Both events will include webcasts accessible through Rain's website, with replays available for 30 days post-presentation. Rain focuses on precision oncology, developing targeted therapies for cancer.

NEWARK, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage company developing precision oncology therapeutics, today announced that Avanish Vellanki, co-founder, chairman and chief executive officer of Rain, will participate in a fireside chat at the Piper Sandler 33^rd Annual Healthcare Conference being held virtually November 29-December 2, 2021 and at the Evercore ISI 4^th Annual Health CONx Virtual Conference being held virtually November 30-December 2, 2021.

Additional details can be found below:

Conference: Piper Sandler 33^rd Annual Healthcare Conference
Date and Time: Prerecorded presentation will be available in advance beginning today, November 22, 2021, at 10:00 a.m. ET
Location: Webcast Link - or at the company’s website (click here)

Conference: Evercore ISI 4^th Annual Health CONx Virtual Conference
Date: Thursday, December 2, 2021
Time: 3:00 p.m. ET
Location: Webcast Link - or at the company’s website (click here)

Replay of the presentations will be available by visiting the "Events & Presentations" section of the Rain website after the conclusion of the presentation and will be archived on the Rain website for 30 days.

About Rain Therapeutics Inc.
Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2, which is oncogenic in numerous cancers. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.

Media Contact
Jordyn Temperato
LifeSci Communications
+1.646.876.5196
jtemperato@lifescicomms.com

Investor Contact:
Bob Yedid
LifeSci Advisors
+1.646.597.6989
bob@lifesciadvisors.com

FAQ

What is the date of the Piper Sandler Healthcare Conference for Rain Therapeutics?

The Piper Sandler 33rd Annual Healthcare Conference will take place virtually from November 29 to December 2, 2021.

When will Avanish Vellanki present at the Piper Sandler Conference?

Avanish Vellanki's prerecorded presentation will be available on November 22, 2021, at 10:00 a.m. ET.

What is the date and time for Rain Therapeutics at the Evercore ISI Conference?

Rain Therapeutics will present at the Evercore ISI 4th Annual Health CONx Conference on December 2, 2021, at 3:00 p.m. ET.

How can I view the presentations for Rain Therapeutics' conferences?

The presentations can be viewed via the webcast links provided on Rain's website, and will be archived for 30 days.

What is Rain Therapeutics developing?

Rain Therapeutics is focused on precision oncology, developing therapies that target oncogenic drivers in cancer.